|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | One Massachusetts Ave. NW |
Address2 | Suite 880 |
| City | Washington |
State | DC |
Zip Code | 20001-1401 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 46131-12
|
||||||||
|
6. House ID# 306460000
|
||||||||
| TYPE OF REPORT | 8. Year | 2018 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Scott Bousum |
Date | 7/10/2018 1:26:23 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
S.1086 and H.R. 5121, bills to amend title 10, United States Code, to remove the prohibition on eligibility for TRICARE Reserve Select of members of the reserve components of the Armed Forces who are eligible to enroll in a health benefits plan under chapter 89 of title 5, United States Code; S. 2416 and
H.R. 5038, Reserve Component Benefits Parity Act of 2018; H.R. 2810, authorizes FY18 appropriations and sets forth policies for the Department of Defense (DOD) programs and activities, including military personnel strengths. It does not provide budget authority, which is provided in subsequent appropriations legislation
H.R. 4633, the Credentialing, Educating, and Relevant Training Initiative for Your Heroes (CERTIFY Heroes) Act. This bill would make a minor amendment to 10 USC 2006a to give people in DOD the ability to use their tuition assistance for any credentials, licenses, or certifications recognized by or necessary for practice in their state.
FY19 Defense Direct Report Language.
Rare Cancers. --- The disproportionate impact of rare cancers on veterans, the number of rare cancers affecting veterans that are understudied and misunderstood, and inadequate treatment options for rare cancers are concerning. Therefore, the Department is instructed to provide a report to the Committees within 90 days of enactment of this Act for each of the last five years: the prevalence rate of rare cancers among veterans; the types of treatments being provided to veterans specifically for rare cancers; any studies on rare cancers conducted by the Department; the Department's expenditures on the treatment of rare cancers; the Department's programs dedicated to addressing rare cancers among veterans; and recommendations on ways the Department can enhance rare cancer treatments for veterans.
H.R. 5515, John S. McCain National Defense Authorization Act for Fiscal Year 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Defense - Dept of (DOD)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Bousum |
Scott |
|
|
|
Daniel |
Elkins |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code EDU
16. Specific lobbying issues
H.R. 4508 Promoting Real Opportunity, Success, and Prosperity through Education Reform (PROSPER) Act. A bill designed to change the landscape of higher education to include new accountability metrics by doing away with gainful employment regulations as well as the 9010 regulation and replacing it with risksharing across all institutions in higher education. In order to support students in completing an affordable postsecondary education that will prepare them to enter the workforce with the skills they need for lifelong success.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Education - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Daniel |
Elkins |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
FY19 MILCON-VA bills Direct Report Language.
Rare Cancers. --- The disproportionate impact of rare cancers on veterans, the number of rare cancers affecting veterans that are understudied and misunderstood, and inadequate treatment options for rare cancers are concerning. Therefore, the Department is instructed to provide a report to the Committees within 90 days of enactment of this Act for each of the last five years: the prevalence rate of rare cancers among veterans; the types of treatments being provided to veterans specifically for rare cancers; any studies on rare cancers conducted by the Department; the Department's expenditures on the treatment of rare cancers; the Department's programs dedicated to addressing rare cancers among veterans; and recommendations on ways the Department can enhance rare cancer treatments for veterans.
17. House(s) of Congress and Federal agencies Check if None
Veterans Affairs - Dept of (VA), U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Daniel |
Elkins |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
FY19 Health bills Direct Report Language.
Rare Cancers. --- The disproportionate impact of rare cancers on veterans, the number of rare cancers affecting veterans that are understudied and misunderstood, and inadequate treatment options for rare cancers are concerning. Therefore, the Department is instructed to provide a report to the Committees within 90 days of enactment of this Act for each of the last five years: the prevalence rate of rare cancers among veterans; the types of treatments being provided to veterans specifically for rare cancers; any studies on rare cancers conducted by the Department; the Department's expenditures on the treatment of rare cancers; the Department's programs dedicated to addressing rare cancers among veterans; and recommendations on ways the Department can enhance rare cancer treatments for veterans.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Daniel |
Elkins |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |